Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21

Cellular Immunology

Volumn 290, Issue 1, 2014, Pages 10-20

  Jiang, Bo ^a   Wu, Xuan ^b   Li, Xi Ning ^a   Yang, Xi ^a   Zhou, Yulai ^a   Yan, Haowei ^a   Wei, An Hui ^a   Yan, Weiqun ^a  

^a JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

4 1BBL; IL 21; K562 cells; MICA; NK cells

Indexed keywords

CD137 LIGAND; GAMMA INTERFERON; INTERLEUKIN 21; MEMBRANE PROTEIN; MICA PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; COCULTURE; CYTOKINE PRODUCTION; CYTOTOXICITY; FEEDBACK SYSTEM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; LYMPHOCYTE DIFFERENTIATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

4-1BBL; IL-21; K562 CELLS; MICA; NK CELLS;

4-1BB LIGAND; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GPI-LINKED PROTEINS; HELA CELLS; HEP G2 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKINS; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IGG;

EID: 84901333121     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.04.011     Document Type: Article

References (41)

1. Timonen T., Saksela E. Isolation of human NK cells by density gradient centrifugation. J. Immunol. Methods 1980, 36:285-291.
2. Robertson M.J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990, 76:2421-2438.
3. Lanier L.L., Le A.M., Civin C.I., et al. The relationship of CD1(Leu-11) and Leu-1(NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 1986, 136:4480-4486.
4. Ferlazzo G., Thomas D., Lin S.L., et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 2004, 172:1455-1462.
5. Cooper M.A., Fehniger T.A., Turner S.C., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001, 97:3146-3151.
6. + NK cells: a functional intermediate stage of NK cell differentiation. J. Immunol. 2011, 186:6753-6761.
7. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
8. bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunol. Immunother. 2012, 61:615-628.
9. Gong W., Xiao W., Hu M., et al. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. Tissue Antigens 2010, 76:467-475.
10. Alderson M.R., Smith C.A., Tough T.W., et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 1994, 24:2219-2227.
11. Cannons J.L., Lau P., Ghumman B., et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T Cells with similar efficacy. J. Immunol. 2001, 167:1313-1324.
12. Maniar A., Zhang X., Lin W., et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010, 116:1726-1733.
13. Zhang H., Cui Y., Voong N., et al. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J. Immunother. 2011, 34:187-195.
14. Steinle A., Li P., Morris D.L., et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001, 53:279-287.
15. Busche A., Goldmann T., Naumann U., et al. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum. Gene Ther. 2006, 17:135-146.
16. Diefenbach A., Jensen E.R., Jamieson A.M., et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature 2001, 413:165-171.
17. Groh V., Wu J., Yee C., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
18. Spolski R., Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 2008, 26:57-79.
19. Asao H., Okuyama C., Kumaki S., et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 2001, 167:1-5.
20. Parrish-Novak J., Dillon S.R., Nelson A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
21. Kasaian M.T., Whitters M.J., Carter L.L., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559-569.
22. Skak K., Frederiksen K.S., Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008, 123:575-583.
23. Valiathan R., Lewis J.E., Melillo A.B., et al. Evaluation of a flow cytometry-based assay for natural killer cell activity in clinical settings. Scand. J. Immunol. 2012, 75:455-462.
24. Terme M., Ullrich E., Delahaye N.F., et al. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 2008, 9:486-494.
25. Kobayashi H., Dubois S., Sato N., et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005, 105:721-727.
26. Fujisaki H., Kakuda H., Shimasaki N., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009, 69:4010-4017.
27. Ofer M., Pratap M., Daniel M., et al. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:5640-5644.
28. Romee R., Foley B., Lenvik T., et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013, 121:3599-3608.
29. States D.J., Walseth T.F., Lee H.C. Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38. Trends Biochem. Sci. 1992, 17:495.
30. Mallone R., Funaro A., Zubiaur M., et al. Signaling through CD38 induces NK cell activation. Int. Immunol. 2001, 13:397-409.
31. Borrego F., Robertson M.J., Ritz J., et al. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999, 97:159-165.
32. Bauer S., Groh V., Wu J., Steinle A., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
33. Gunturi A., Berg R.E., Forman J. The role of CD94/NKG2 in innate and adaptive immunity. Immunol. Res. 2004, 30:29-34.
34. Vales-Gomez M., Reyburn H.T., Erskine R.A., et al. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999, 18:4250-4260.
35. + NK-cell subset. Blood 2010, 116:3865-3874.
36. Ida H., Robertson M.J., Voss S., et al. CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells. J. Immunol. 1997, 159:2154-2160.
37. Hussell T., Openshaw P.J. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J. Gen. Virol. 1998, 79:2593-2601.
38. Lee I.F., Qin H., Priatel J.J., et al. Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes. Eur. J. Immunol. 2008, 38:82-89.
39. Matikainen S., Paananen A., Miettinen M., et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur. J. Immunol. 2001, 31:2236-2245.
40. He X.S., Draghi M., Mahmood K., et al. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J. Clin. Invest. 2004, 114:1812-1819.
41. Zhang S., Saha B., Kodys K., et al. IFN-gamma production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J. Hepatol. 2013, 59:442-449.